

## HR 5031

Medical Innovation Act of 2019

**Congress:** 116 (2019–2021, Ended)

**Chamber:** House

**Policy Area:** Health

**Introduced:** Nov 8, 2019

**Current Status:** Referred to the Subcommittee on Health.

**Latest Action:** Referred to the Subcommittee on Health. (Nov 12, 2019)

**Official Text:** <https://www.congress.gov/bill/116th-congress/house-bill/5031>

### Sponsor

**Name:** Rep. Welch, Peter [D-VT-At Large]

**Party:** Democratic • **State:** VT • **Chamber:** Senate

### Cosponsors

*No cosponsors are listed for this bill.*

### Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred to	Nov 12, 2019

### Subjects & Policy Tags

**Policy Area:**

Health

### Related Bills

Bill	Relationship	Last Action
116 S 3163	Related bill	<b>Jan 8, 2020:</b> Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

## **Medical Innovation Act of 2019**

This bill requires certain drug manufacturers to make payments to fund research supported by the Food and Drug Administration (FDA) and the National Institutes of Health (NIH).

A drug manufacturer with over \$1 billion in net income in a fiscal year that has entered into a relevant settlement agreement regarding specified violations must pay 0.75%-1.5% of its net income to the Department of Health and Human Services for each of its covered blockbuster drugs. A covered blockbuster drug is a drug that has at least \$1 billion in net sales in a year and was developed, in whole or in part, through federal investments in medical research.

Payments are divided between the FDA and the NIH in proportion to the discretionary funding of those agencies, excluding FDA user fees. Payments are not disbursed if appropriations for the FDA or the NIH are lower than in the prior fiscal year. Priorities for payments must include advancing regulatory science for medical products and research related to diseases that disproportionately account for federal health care spending.

A covered blockbuster drug for which a manufacturer has not made a required payment is considered misbranded and subject to prohibitions on introducing or receiving misbranded drugs in interstate commerce.

## **Actions Timeline**

---

- **Nov 12, 2019:** Referred to the Subcommittee on Health.
- **Nov 8, 2019:** Introduced in House
- **Nov 8, 2019:** Referred to the House Committee on Energy and Commerce.